Publications:133
Video Visit Available
Accepting New Patients
- Mount Sinai Doctors
- Treats Adults
- Video Visit Available
- Accepting New Patients
Samir Parekh, MBBS
Cancer (Oncology), Hematology-Oncology
About Me
Samir Parekh, MBBS, is Professor of Medicine (Hematology and Medical Oncology) and Oncological Sciences at the Icahn School of Medicine at Mount Sinai. He is Director of the Center of Excellence for Multiple Myeloma and Section Head of Multiple Myeloma in the Division of Hematology and Medical Oncology. Dr. Parekh is Co-Leader of the Cancer Clinical Investigation program at The Tisch Cancer Institute at Icahn Mount Sinai and a faculty member of the Icahn Genomics Institute and Marc and Jennifer Lipschultz Precision Immunology Institute.
Dr. Parekh's research focuses on the pathogenesis of hematological malignancies and development of individualized, precision-medicine therapies for these malignancies. His lab uses an integrated systems biology approach to study genome-wide methylation, gene expression and DNA sequence variation to understand pathogenesis, develop biomarkers and guide personalized therapy in B cell malignancies, particularly multiple myeloma and Non-Hodgkin's lymphoma.
Dr. Parekh currently serves on grant review committees for the National Institutes of Health, Department of Defense and Multiple Myeloma Research Foundation; he is a member of the American Society of Hematology Plasma cell committee and the American Society of Clinical Investigation. Dr. Parekh has led innovative investigator-initiated precision medicine trials testing novel small molecules and NGS-guided drug repurposing using RNA-and DNA-sequencing to salvage end-stage myeloma patients. His lab has served as an international reference unit for studying the immune effects of novel cereblon modulators (Celmods) Iberdomide and Mezigdomide. His observations on the side effects of CART and bispecific therapy have led to increased safety, better patient selection and awareness of infectious complications of these powerful novel therapeutics.
Language
English
Position
PROFESSOR | Medicine, Hematology and Medical Oncology, PROFESSOR | Oncological Sciences, PROFESSOR | Immunology & Immunotherapy
Hospital Affiliations
- Mount Sinai Beth Israel
- Mount Sinai Morningside
- Mount Sinai Brooklyn
- Mount Sinai Queens
- The Mount Sinai Hospital
- Mount Sinai West
Research Topics
Computational Biology, Drug Resistance, Epigenetics, Lymphoma, Transcriptional Activation and Repression
Multi-Disciplinary Training Areas
Cancer Biology [CAB], Disease Mechanisms and Therapeutics (DMT)
Download the CVClinical Focus
- Cancer
- Multiple Myeloma
- Smoldering Myeloma
Education
MD, KJ Somaiya Medical College
Residency, Internal Medicine
John H Stroger Jr Hospital of Cook County
Fellowship, Hematology & Oncology
Montefiore/Albert Einstein College of Medicine Rheumatology
Certifications
American Board of Internal Medicine
Awards
2005
Young Investigator Award
ASCO
Young Investigator Travel Award
ECOG
First Overall and Highest Rank in General Internal Medicine
K.J. Somaiya Medical College
Research
With the advent of next-generation sequencing, we have been systematically developing and studying the application of integrative genomics (including methylation, gene expression and exome sequencing) to guide personalized repurposing of FDA approved drugs to overcome chemotherapy resistance in B cell malignancies like non-Hodgkins Lymphoma and Multiple Myeloma. I have an ongoing IRB approved clinical trial for genomic signature guided therapeutic selection in collaboration with Drs. Jagannath and Schadt, Dean for Precision Medicine and the Jean C. and James W. Crystal Professor of Genomics at the Icahn School of Medicine at Mount Sinai.
Insurance Information
Accepted insurance may vary by the doctor’s office location. Please contact the office directly to obtain the most up-to-date insurance information.
- 1199 SEIU
- AETNA - Commercial
- AETNA - Medicare
- Affinity Medicaid-Medicare-Essential Exchange
- Amidacare Medicaid
- CIGNA Healthcare
- Centivo
- Elderplan
- EmblemHealth - GHI-PPO
- EmblemHealth - HIP
- EmblemHealth - HIP-Medicaid
- EmblemHealth - HIP-Medicare
- Empire Blue Cross Blue Shield - Commercial/Exchange
- Empire Blue Cross Blue Shield - HealthPlus Medicaid
- Empire Blue Cross Blue Shield - Medicare
- Fidelis Health Care
- HealthFirst Medicaid
- HealthFirst Medicare
- Horizon NJ
- Magnacare-Health Care
- Medicare - NJ
- Medicare - NY
- Metroplus
- Multiplan PHCS
- NJ Medicaid
- NY Medicaid
- Oscar
- Oxford - Freedom and Liberty
- Partners Health Plan
- Senior Whole Health
- United Health Care - Commercial
- United Health Care - Empire Plan
- United Health Care - Oxford Care
- United Health Care - Top Tier
- VNSNY Choice Medicare
- VNSNY Select Health Medicaid
- VillageCareMax
- WellCare Health Plan
Physicians who provide services at hospitals and facilities in the Mount Sinai Health System might not participate in the same health plans as those Mount Sinai hospitals and facilities (even if the physicians are employed or contracted by those hospitals or facilities).
Information regarding insurance participation and billing by this physician may be found on this page, and can also be obtained by contacting this provider directly. Because physicians insurance participation can change, the insurance information on this page may not always be up-to-date. Please contact this physician directly to obtain the most up-to-date insurance information.
Insurance and health plan networks that the various Mount Sinai Health System hospitals and facilities participate in can be found on the Mount Sinai Health System website.
Publications
Selected Publications
- CEACAM1 as a mediator of B-cell receptor signaling in mantle cell lymphoma. Serene Xavier, Vivian Nguyen, Vishal Khairnar, An Phan, Lu Yang, Michael S. Nelson, Ravi P. Shukla, Jinhui Wang, Aimin Li, Huimin Geng, Jaewoong Lee, Teresa Sadras, Lan V. Pham, Dennis D. Weisenburger, Wing C. Chan, Karl S. Lang, Geoffrey P. Shouse, Alexey V. Danilov, Joo Y. Song, Samir Parekh, Markus Müschen, Vu N. Ngo. Nature Communications
- Erratum: International Myeloma Society/International Myeloma Working Group Consensus Recommendations on the Definition of High-Risk Multiple Myeloma (Journal of Clinical Oncology (2025) DOI: 10.1200/JCO-24-01893). Hervé Avet-Loiseau, Faith E. Davies, Mehmet K. Samur, Jill Corre, Mattia D'agostino, Martin F. Kaiser, Marc S. Raab, Niels Weinhold, Norma C. Gutierrez, Bruno Paiva, Paola Neri, Katja Weisel, Francesco Maura, Brian A. Walker, Mark Bustoros, A. Keith Stewart, Saad Z. Usmani, Jens Hillengass, Wee Joo Chng, Jonathan J. Keats, Joaquin Martinez-Lopez, Adam S. Sperling, Cyrille Touzeau, Fenghuang Zhan, Noopur S. Raje, Michele Cavo, Niccolò Bolli, Irene M. Ghobrial, Madhav V. Dhodapkar, Sundar Jagannath, Andrew Spencer, Samir Parekh, Nizar J. Bahlis, Sagar Lonial, Pieter Sonneveld, Leif Bergsagel, Robert Z. Orlowski, Gareth Morgan, María Victoria Mateos, S. Vincent Rajkumar, Jesus F.San Miguel, Kenneth C. Anderson, Philippe Moreau, Shaji Kumar, Felipe Prósper, Nikhil C. Munshi. Journal of Clinical Oncology
- PGV001, a Multi-Peptide Personalized Neoantigen Vaccine Platform: Phase I Study in Patients with Solid and Hematologic Malignancies in the Adjuvant Setting. Mansi Saxena, Thomas U. Marron, Julia Kodysh, John P. Finnigan, Sayali Onkar, Anna Kaminska, Kevin Tuballes, Ruiwei Guo, Rachel Lubong Sabado, Marcia Meseck, Timothy J. O’donnell, Robert P. Sebra, Samir Parekh, Matthew D. Galsky, Ana Blasquez, Gustavo Gimenez, Mesude Bicak, Cansu Cimen Bozkus, Daniela Delbeau-Zagelbaum, Denise Rodriguez, Ana Acuna-Villaorduna, Krzysztof J. Misiukiewicz, Marshall R. Posner, Brett A. Miles, Hanna Y. Irie, Amy Tiersten, Deborah B. Doroshow, Andrea Wolf, John Mandeli, Rachel Brody, Andres M. Salazar, Sacha Gnjatic, Jeff Hammerbacher, Eric Schadt, Philip Friedlander, Alexander Rubinsteyn, Nina Bhardwaj. Cancer Discovery
Industry Relationships
Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device, biotechnology companies, and other outside entities to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their outside financial relationships.
Below are financial relationships with industry reported by Dr. Parekh during 2024 and/or 2025. Please note that this information may differ from information posted on corporate sites due to timing or classification differences.
Consulting or Other Professional Services Examples include, but are not limited to, committee participation, data safety monitoring board (DSMB) membership
- Genentech, Inc.
- GRAIL, Inc
- Regeneron Pharmaceuticals, Inc.
- Janssen Pharmaceuticals
Mount Sinai’s faculty policies relating to faculty collaboration with industry are posted on our website. Patients may wish to ask their physician about the activities they perform for companies.